Table 1.

Exosomal protein markers in multiple cancers

Tumor types	Body fluids	Enrichment method	Signature or pool in exosomes	Application	Ref.
Pancreatic cancer	Patients' blood	Ultracentrifugation	Glypican-1	Diagnosis	59
	Medium	Ultracentrifugation	CD151, ADAM1 and ADAM15	Prognosis	91
	Patients' plasma	Ultracentrifugation	MIF	Prognosis and treatment	60
	Patients' serum	Ultracentrifugation	vimentin	Diagnosis and treatment	61
Melanoma	Patients' plasma	Ultracentrifugation	TYRP2, VLA-4, HSP70, HSP90 and MET	Prognosis and treatment	92
	Patients' serum	Ultracentrifugation	MIA and S100B	Prognosis and diagnosis	93
Lung cancer	Urine	Ultracentrifugation	LRG1	Diagnosis	94
	Saliva	Ultracentrifugation	BPIFA1, CRNN, MUC5B, and IQGAP	Detection	95
	Medium	ExoQuick-TC™ kit	Vasorin	Treatment	96
	Patients' blood	Ultracentrifugation	LG3BP and PIGR	Diagnosis	97
Glioblastoma	Medium	Ultracentrifugation	angiogenin, IL-6 and IL-8	Detection and diagnosis	98
Gastric cancer	Medium	Ultracentrifugation	EGFR	Detection and diagnosis	10
Colorectal cancer	Patients' blood	Ultracentrifugation	CD147	Detection and diagnosis	99
	Patients' plasma	ExoCapTM kit	GPC1	Diagnosis and treatment	100
Ovarian cancer	Ascytic fluid	Ultracentrifugation	CD24	Diagnosis	101
	Ascitic Fluid	Ultracentrifugation	TGM2, U2AF1, U2AF2, and HNRHPU	Diagnosis	102
Cholangiocarcinoma	Patients' blood	Ultracentrifugation	VNN1, CRP, FIBG, IGHA1, and A1AG1	Diagnosis	97
Prostate cancer	Urine	Ultracentrifugation	PCA3	Diagnosis and monitoring	103
Glioma	Cerebrospinal fluid	Ultracentrifugation	IL13QD	Detection and recurrence	104